Tiziana Life Sciences CEO Updates Shareholders on its Patent Portfolio, Clinical Pipeline, and Strategy in an Exclusive Interview

NEW YORK and LONDON, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, today announced that an interview with its CEO and CSO Dr. Kunwar Shailubhai is now available.  In the interview, Dr. Shailubhai updates shareholders on its recently issued patents: Methods and use of anti-CD3 monoclonal antibodies for treatment of Crohn’s Disease, including Tiziana’s lead drug Foralumab, the first and only fully human monoclonal antibody Methods and use of anti-IL-6/IL-6 receptor monoclonal antibodies as prophylactic and therapeutic interventions for human diseases, including COVID-19 and other pulmonary diseases Use of Milciclib in combination with a Tyrosine Kinase Inhibitor such as Sorafenib or Regorafenib for treatment of hepatocellular carcinoma and other cancers Dr. Shailubhai also comments on the Tiziana’s clinical pipeline and near-term milestones for reporting data for its oral and nasal Phase 2 clinical studies with Foralumab and its plans for clinical development of TZLS-501, a novel fully human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody for COVID-19. The interview also provides an update on the plan for treatment of hepatocellular carcinoma with its lead drug Milciclib. To watch To keep reading about Tiziana Life Sciences CEO Updates Shareholders on its Patent Portfolio, Clinical Pipeline, and Strategy in an Exclusive Interview, Click on the link. Seoul, Korea
http://dlvr.it/RfR6Sg

Comments

Post a Comment

Popular posts from this blog

AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts

Image
(RTTNews) - AstraZeneca Plc (AZN.L, AZN) said first participants have been dosed in a Phase I trial of AZD7442 for the prevention and treatment of COVID-19. The trial will evaluate the safety, tolerability and pharmacokinetics of AZD7442. It will include up to 48 healthy participants in the UK aged 18 to 55 years. AZD7442 is a combination of two monoclonal antibodies derived from convalescent patients with SARS-CoV-2 infection. Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the mAbs were optimised by AstraZeneca. Data readout from the trial is anticipated in the second half of 2020. To keep reading about AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts, Click on the link. Seoul, Korea http://dlvr.it/RfHgSK
Read more

AT&T Sells DirecTV Stake To Private Equity Firm TPG

News, market analysis, investment scam prevention tips and more ✔️ Your source for latest asset management news and information. This magazine is crafted specifically for those who are interested in diving into the global asset management world. (RTTNews) - AT&T Inc. (T) has reached a deal with private equity firm TPG Capital to make its struggling satellite TV provider DirecTV a new standalone company. The deal will establish a new company that will own and operate AT&T's U.S. video business unit consisting of the DirecTV, AT&T TV and U-verse video services. The new company will have an enterprise value of $16.25 billion. The company will be jointly governed by a board with two representatives from each of AT&T and TPG, as well as a fifth seat for the CEO, which at closing will be Bill Morrow, CEO of AT&T's U.S. video unit. Following the close of the transaction, AT&T will own 70% of the common equity and TPG will own 30%. AT&T will receive $7...
Read more

7 lies to stop telling yourself if you want to become mentally stronger

Image
Crystal Cox/Business Insider Amy Morin is a psychotherapist, licensed clinical social worker, mental strength coach, and international bestselling author. She explains that sometimes our own thoughts can hold us back, especially if we tend to dwell on negative events, insecurities, and self-doubt. Morin says it's important to confront thoughts like "I'm not good enough" or "I'm too damaged," and replace them with self-empathy by instead saying "I am worth it" or "I'm a survivor." Visit Business Insider's homepage for more stories. Many of the things you tell yourself aren't true. And there's a good chance you've bought into some unhealthy beliefs over the years. Courtesy of Amy Morin In the therapy world, we call these "cognitive distortions." We all have them. Learning to recognize these lies we tell ourselves and replace them with healthier, more realistic statements is key to building mental str...
Read more